Latus Bio’s new AAV capsids reach 80% of kidney glomeruli, but can better delivery translate into safer gene therapies?
Latus Bio reports AAV capsids reaching 80% of kidney glomeruli and up to 60% of cortical neurons, with human safety and efficacy unproven.